Top Stories
Breast-Conserving Surgery Plus Radiotherapy May Yield Better Survival Than Mastectomy With or Without Radiotherapy

de Boniface et al find that breast-conserving surgery plus RT for women with breast cancer is associated with better survival vs mastectomy with or without RT in analysis adjusting for...

The ASCO Post
Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer

For patients with resectable stage IIIA NSCLC, neoadjuvant CT with cisplatin and docetaxel followed by surgery resulted in a 1-year EFS rate of 48% in the SAKK 16/00 trial and is an accepted...

Journal of Clinical Oncology

Head And Neck Cancer

Patterns of Technology Use Among Patients With Head and Neck Cancer and Implications for Telehealth

The objective of this study is to describe baseline technology use within the head and neck cancer population prior to the COVID-19 pandemic.

OTO Open
Human Adipose-Derived Stem/Stromal Cells Promote Proliferation and Migration in Head and Neck Cancer Cells

Although clinical studies on the subject of oncological safety are still needed, these findings emphasize the importance of complete tumor removal before ASCs are used in the head and neck.

Saliva Test to Detect HPV-Associated Throat Cancer

A novel saliva test has been shown to detect HPV-associated oropharyngeal squamous cell carcinoma with high accuracy in a small study.

Systematic Analysis of Survival-Associated Alternative Splicing Signatures in Thyroid Carcinoma

Study investigators use TCGA to generate AS maps in patients with thyroid cancer.

Frontiers in Oncology
Molecular Interplays Between Cell Invasion and Radioresistance That Lead to Poor Prognosis in Head-Neck Cancer

In this study, investigators hypothesize that HNC cells might exhibit a cross-phenotypic attribute between cell invasion and radioresistance.

Frontiers in Oncology
Predictive Value of Skeletal Muscle Mass in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors

Study investigators evaluate the impact of skeletal muscle index on prognosis and immune-related adverse events in a cohort of recurrent/metastatic HNSCC treated with ICIs.

Frontiers in Oncology

FDA Approvals

FDA Approves Belumosudil for Chronic Graft-vs-Host Disease

The FDA approves belumosudil for adult and pediatric patients aged 12 years and older with chronic GvHD after failure of at least two prior lines of systemic therapy.

The ASCO Post
FDA Grants Regular Approval to Enfortumab Vedotin-ejfv for Locally Advanced or Metastatic Urothelial Cancer

The FDA approved enfortumab vedotin-ejfv for adult patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor and platinum-containing CT..

The ASCO Post
FDA Grants Regular Approval to Pembrolizumab/Lenvatinib for Advanced Endometrial Carcinoma

The FDA approves pembrolizumab in combination with lenvatinib for patients with advanced endometrial carcinoma that is not MSI-H or dMMR who have disease progression following...

The ASCO Post
FDA Approves Expanded Indication for Pembrolizumab in Locally Advanced Cutaneous Squamous Cell Carcinoma

The FDA approves an expanded label for pembrolizumab, an anti–PD-1 agent, as monotherapy for patients with locally advanced cSCC that is not curable by surgery or radiation.

The ASCO Post
FDA Approves Pembrolizumab in Combination for High-Risk, Early-Stage TNBC

The FDA approves pembrolizumab for high-risk, early-stage TNBC in combination with CT as a neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.

The ASCO Post


Development and Optimization of Clinical Informatics Infrastructure to Support Bioinformatics at an Oncology Center.

Translational bioinformatics for therapeutic discovery requires the infrastructure of clinical informatics.

Methods of Molecular Biology
Pharmacogenomics in Pediatric Oncology: Mitigating Adverse Drug Reactions While Preserving Efficacy

Major developments in drugs such as thiopurines and optimization in clinical trial protocols for treating cancer in children have led to a remarkable improvement in survival, from approximately...<

Annual Review of Pharmacology and Toxicology
Selecting Image-Guided Surgical Technologies in Oncology: A Surgeon's Perspective.

This study aimed to select the most promising IG technology per oncologic indication.

Journal of Surgical Research
The use of Hericium erinaceus and Trametes versicolor extracts in supportive treatment in oncology.

Substances available in nature with potential therapeutic effects are the subject of research that raises tremendous hopes for new challenges medicine.

Acta Pharmaceutica
Review of Oncology and Transplant Literature for the Management of Hepatic and Pancreatic Resections in Jehovah's Witnesses.

Jehovah's Witnesses undergoing liver or pancreas surgery represent a unique medical and ethical challenge.

Cancer medicine journal

Lung Cancer

Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer

Combination therapy with nivolumab and ipilimumab is currently only indicated as first-line therapy in patients with advanced non–small-cell lung cancer.

JAMA Oncology
Are Patients With Primary Lung Cancer Detected by Low-Dose CT at Reduced Risk of Brain Metastases?

Patients with primary lung cancer detected using low-dose computed tomography screening may be at reduced risk for developing brain metastases after diagnosis, according to a study published...

The ASCO Post
Comprehensive Dissection of Treatment Patterns and Outcome for Patients With Metastatic Large-Cell Neuroendocrine Lung Carcinoma

Study investigators retrospectively analyze all patients with metastatic large-cell neuroendocrine lung carcinoma in the records of a large German academic center since 2010.

Frontiers in Oncology
Missing Protein in SCLC May Explain Poor Response to Immunotherapies

A new study reveals that a key surface protein, NKG2DL (natural killer group 2, member D ligand), that typically triggers an immune response is missing in most SCLC tumors.

Oncology Times - Latest Articles
BMI May Not Be Best Obesity Indicator to Assess Risk for Lung Cancer

New research published in the Journal of Thoracic Oncology suggests the method used to calculate how obesity is measured may affect whether it is considered a risk factor for lung cancer.

Oncology Times - Latest Articles
The Effect of Smoking Status on Efficacy of Immune Checkpoint Inhibitors in Metastatic Non–Small-Cell Lung Cancer

Study investigators examine whether or not smoking status can effect efficacy of ICIs in metastatic non–small-cell lung cancer. 


Immuno Oncology

Cardiovascular Risks Associated With Checkpoint Inhibitors and CAR T-Cell Therapy

Leveraging the immune system to treat cancer, however, also increases the potential for serious off-target effects.

The ASCO Post
Comprehensive Transcriptomic Analysis Reveals the Role of the Immune Checkpoint HLA-G Molecule in Cancers

The aim of this study is to systematically identify the roles of checkpoint HLA-G molecules across various types of cancer.

Frontiers in Immunology
mRNA in Cancer Immunotherapy: Beyond a Source of Antigen

Many novel immunotherapeutic strategies focus on the use of mRNA beyond its use as the source of tumor antigens. 

Molecular Cancer
Clinical Sequencing to Assess Tumor Mutational Burden as a Useful Biomarker to Immunotherapy in Various Solid Tumors

Tumor mutational burden has been considered as a useful marker to indicate patients who benefit from ICIs.

Therapeutic Advances in Medical Oncology
Immune Regulation of the cGAS-STING Signaling Pathway in the Tumor Microenvironment and Its Clinical Application

STING agonists, as novel agonists, are used in preclinical research and in the treatment of various tumors via clinical trials and have displayed attractive application prospects.

OncoTargets and Therapy
Standardization & Harmonization of Immuno-Oncology Toxicities

A report from the Association of Community Cancer Centers shows that IO treatment is increasingly being given to patients in community settings, not just in academic cancer centers.

Oncology Times - Latest Articles

Gastrointestinal Cancer

Disease-Specific Survival of AJCC 8th Stage II Gastric Cancer Patients After D2 Gastrectomy

The purpose of this study is to investigate the independent risk factors for treatment failure in stage II gastric cancer.

Frontiers in Oncology
Identification and Validation of the Immune Regulator CXCR4 as a Novel Promising Target for Gastric Cancer

This study has determined the prognostic value of 11 immunomodulatory factors in gastric cancer.

Frontiers in Immunology
KIT Inhibitor Combination Shows Efficacy in Refractory GIST

Investigators find that the combination of a type I KIT inhibitor, PLX9486, with the type II inhibitor sunitinib produces clinical benefit and improves PFS rates in patients with GIST.

The ASCO Post
Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

In May 2021, nivolumab was approved for adjuvant treatment of patients with completely resected esophageal or GEJ cancer with residual pathologic disease after neoadjuvant chemoradiotherapy.

The ASCO Post
Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors

This study seeks to answer the question: Is cotargeting the active and inactive conformations of KIT associated with clinical benefit in refractory GIST?

JAMA Oncology

Skin Cancer

Ultrasound-Mediated Microbubble Destruction Inhibits Skin Melanoma Growth by Affecting YAP1 Translation Using Ribosome Imprinting Sequencing

In this study, tumor tissue samples are collected from 64 CMM patients.

Frontiers in Oncology
PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma

Investigators retrospectively analyze plasma DNA of patients with advanced melanoma treated with PD-1 antibodies, nivolumab or pembrolizumab, for five PD-1 genotype single nucleotide polymorphisms.

Frontiers in Immunology
High-Dose Interferon or Ipilimumab vs Pembrolizumab for High-Risk Resected Melanoma

Patients with high-risk melanoma who had a course of pembrolizumab had longer recurrence-free survival than patients who received either ipilimumab or high-dose interferon after surgery.

The ASCO Post
Immunotherapy Combo Checks Progression in Advanced Melanoma

Researchers have used two immunotherapy drugs to target and block different protein checkpoints, significantly increasing the time before melanoma progressed in new patients with...

Oncology Times - Latest Articles
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma

This phase II cohort from PIVOT-02 study evaluates the CD122-preferential interleukin-2 pathway agonist bempegaldesleukin plus nivolumab in first-line metastatic melanoma.

Journal of Clinical Oncology

Gynecologic Cancer

Identification of Methylation-Driven Genes Prognosis Signature and Immune Microenvironment in Uterus Corpus Endometrial Cancer

This study examines whether abnormal DNA methylation can predict the prognosis of uterus corpus endometrial cancer and reflect the patient's tumor immune microenvironment.

Cancer Cell International
Chemo After Chemoradiation Does Not Extend Survival in Cervical Cancer

Adding chemotherapy after standard chemoradiation treatment does not improve survival for women with locally advanced cervical cancer, and it also leads to additional side effects.

Oncology Times - Latest Articles
Support Vector Machine Model Predicts Dose for Organs at Risk in High-Dose Rate Brachytherapy of Cervical Cancer

This study aims to establish a support vector machine model to predict the dose for organs at risk in intracavitary brachytherapy planning for cervical cancer with tandem and ovoid treatments.

Frontiers in Oncology
Other HPV-Related Cancers Set to Overtake Cervical Cancer by 2025

The incidence of other HPV-associated cancers is rising and could soon surpass cervical cancer, a researcher told a press briefing held in advance of the 2021 ASCO Annual Meeting. 

Oncology Times - Latest Articles
CDC Notes Sharp Declines in Breast and Cervical Cancer Screening


The data show the total number of screenings funded by the NBCCEDP declined by 87% for breast cancer screening and by 84% for cervical cancer screening in April 2020 in comparison...

HER2-Specific CAR T-Cell Trial Addresses Pediatric Brain and Spinal Cord Tumors

The phase I BrainChild-01 trial is assessing the safety and efficacy of delivering repetitive doses of T cells into the brain or the cerebrospinal fluid of children and young adults with R/R tumors

The ASCO Post


FDA Approves Pembrolizumab in Combination for High-Risk, Early-Stage TNBC

The FDA approves pembrolizumab for high-risk, early-stage TNBC in combination with CT as a neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.

The ASCO Post
Lack of Intrafollicular Memory CD4 + T Cells is Predictive of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma

Lack of intrafollicular CD4 expression predicts early failure in FL and combined with FLIPI improves identification of high-risk patients.

Blood Cancer Journal
Correlation Between Early Endpoints and Overall Survival in Non–Small-Cell Lung Cancer

Using multiple source databases, study investigators compile a data set including 81 phase II–IV RCTs of patients with non–small-cell lung cancer.

Frontiers in Oncology
Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia and Richter’s Transformation

RIC-HSCT yields favorable outcomes for patients with high-risk CLL-RT, especially when performed in early remission.

Blood Advances
Novel Monoclonal Antibody Emerges as Potential First-Line Standard in Nasopharyngeal Cancer

A new first-line standard of care may be emerging for recurrent or metastatic nasopharyngeal carcinoma, based on the findings of the global phase III JUPITER-02 trial...

The ASCO Post
Task Force Finalizes New Colorectal Cancer Screening Recommendation

The US Preventive Services Task Force has published a final recommendation statement calling for individuals to get their first CRC screening at age 45 instead of waiting until age 50.

Oncology Times - Latest Articles

source list reference



Addition of AKT Inhibitor Ipatasertib to Abiraterone/Prednisolone in mCRPC With PTEN Loss
The ASCO Post
HER2-Targeted Therapies Demonstrate Activity in a Range of Solid Tumor Types
Cancer Therapy Advisor
Identification and Validation of the Immune Regulator CXCR4 as a Novel Promising Target for Gastric Cancer
Frontiers in Immunology